GenePath Dx

What GenePath Dx does

GenePath Diagnostics is a privately-held molecular diagnostics company founded in 2008 in Pune, India, by Dr. Nikhil Phadke (PhD Molecular, Cellular, and Developmental Biology, University of Michigan). The company operates across 10 countries through a dual structure: an NABL-accredited clinical laboratory in Pune serving the Indian market and an Ann Arbor, Michigan facility supporting the manufacture of custom RUO reagents for the US and international product sales (kits, assays, and platforms) across Europe, Africa, the Middle East, and Southeast Asia within territory-specific regulatory frameworks. As of 2023, the company is led by CEO Dr. Nickhil Jakatdar (PhD EECS, UC Berkeley), whose prior ventures generated over $1.2 billion in value, and a newly assembled executive team covering technology, revenue, finance, regulatory, and North American sales.

Name

GenePath Dx

Legal name

GenePath Diagnostics

Website

https://genepathdx.com

Company type

Private

Founded year

2008

Operating status

Operating

Headcount range

51–100 employees

Short description

GenePath Diagnostics is a privately-held molecular diagnostics company operating an NABL-accredited clinical laboratory in Pune, India and selling custom RUO reagents, diagnostic kits, and platforms to laboratories across 10 countries spanning infectious disease, oncology, hematology, and genetic disorder testing.

Ownership category

akta.pro rank

Product category

Molecular Diagnostics

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)

akta.pro primary industry

Molecular Diagnostics (PCR/qPCR, NGS-based assays) (HLAAALAA)

akta.pro secondary industries

Molecular Diagnostics (PCR/NAAT/NGS-based IVD) (HLAHAAAD), Molecular POCT / NAAT Systems (PCR/Isothermal platforms & cartridges) (HLAHAOAI), Companion Diagnostic (CDx) Co-Development Services (biopharma partnerships, clinical strategy) (HLAAAMAB)

Keywords

• Molecular diagnostics
• PCR test kits
• Clinical genetic testing
• Custom RUO reagents
• In vitro diagnostics

Headquarters

HQ city

Ann Arbor

HQ country

United States

HQ region

North America

Offices5 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Clinical Diagnostic Services (India): Clinical molecular diagnostic and genomic testing services provided directly to healthcare providers and patients in India through their NABL approved laboratory in Pune. Services span infectious diseases, oncology, and genetic disorders. Revenue generated from test fees with turnaround times ranging from 1 day to 5 weeks depending on test complexity.
2. Custom Manufactured Reagents (Global RUO Market): Sale of custom manufactured molecular and genomic reagents for research use only (RUO) market, primarily in the United States. Products include primer-probe mixes for real-time PCR, synthetic plasmids for quality control, and multiplexed assay reagents across oncology, infectious diseases, and genetic disorders.
3. Diagnostic Test Kits and Platforms (International): Sale of assays, platforms, and kits to international markets including Europe, Africa, Middle East, and Southeast Asia. Products are sold within appropriate regulatory frameworks in each territory. The company offers comprehensive diagnostic solutions rather than individual components.
4. Corporate Wellness Screening Programs: Companies pay for cervical cancer screening of female employees and relatives as part of corporate wellness initiatives. This B2B2C model generates revenue while addressing public health objectives.
5. Direct-to-Consumer Testing (Emerging): Direct-to-consumer DNA-based HPV testing with home self-collection kits, launched for Indian market. Targets educated women who prefer privacy and convenience over clinical visits. Consumer pays for kit and testing service.

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels6 records

Core offering

GenePath Dx develops, manufactures, and provides in vitro molecular diagnostics solutions for infectious diseases, oncology, and genetic disorders. In India, it operates an NABL-accredited clinical laboratory delivering molecular diagnostic and genomic testing services to healthcare providers. Globally, it sells custom manufactured research-use-only (RUO) reagents and diagnostic kits/platforms to research laboratories across the US, Europe, Africa, Middle East, and Southeast Asia.

Product overview

GenePath Dx operates as a molecular diagnostics company offering a portfolio of products and services for infectious diseases, oncology, and genetic disorders. The core offering consists of custom manufactured research-use-only reagents (including STI, UTI, Wound, Fungal/Nail, Respiratory, GI, AMR, CNS Meningitis panels) and specialized assay kits (CoviFlu v2.1, Chikungunya-Dengue Multiplex RT-PCR, BCR-ABL IS RQ-PCR, JAK2 v2 qPCR, CMV qPCR, EBV qPCR). These are complemented by proprietary technology platforms: CODE-SEQ for multi-aberration detection, PCR-based technologies, Fragment Analysis (MLPA, MSI, TP-PCR), and Sequencing Technologies (Sanger and NGS). For the India market, GenePath provides clinical diagnostic services through its NABL-approved laboratory. A direct-to-consumer HPV self-collection test is planned for beta launch.

Differentiator

Problem solved

Functional benefit

Products and services

• Custom Multiplex qPCR Reagents (RUO) Custom manufactured research-use-only multiplexed qPCR reagents covering panels for Sexual Transmitted Infections, Urinary Tract Infections, Wound infections, Fungal infections, Respiratory diseases, Gastrointestinal infections, Antimicrobial Resistance markers, and CNS/Meningitis pathogens. Targets research laboratories globally.
• CoviFlu v2.1 RT-qPCR Kit Single tube multiplex RT-qPCR kit for simultaneous detection of SARS-CoV-2, Influenza A, and Influenza B from nasopharyngeal, oropharyngeal, or nasal swab specimens. Features UNG/dUTP system to minimize carry-over contamination. Includes human RNAse P endogenous process control. Limit of Detection: SARS-CoV-2 0.5 copies/μL, Influenza A 1 copy/μL, Influenza B 10 copies/μL.
• Chikungunya-Dengue Multiplex RT-PCR Kit One-step single tube multiplexed assay for detection of Chikungunya and Dengue viruses (all four serotypes) from EDTA peripheral blood or plasma samples.
• BCR-ABL IS RQ-PCR Kit Single-pot duplex assay with integrated reverse transcription for Minimal Residual Disease (MRD) determination. Reports BCR-ABL/ABL ratio on International Scale (IS). Limit of detection: 0.0032% (4.49 log reduction).
• JAK2 v2 Real Time qPCR Kit Detection assay for JAK2 V617F mutation in genomic DNA, with standards provided for quantifying relative Mutant Allele Frequency (MAF). Limit of detection: 1% relative MAF.
• Cytomegalovirus (CMV) qPCR Kit Highly specific multiplexed assay with four target genes for detection and quantification of Cytomegalovirus (CMV) from EDTA peripheral blood, including an internal process control.
• Epstein-Barr Virus (EBV) qPCR Kit Highly specific multiplexed assay with two target genes for detection and quantification of Epstein-Barr virus (EBV), including human RNAse P as endogenous process control.
• Clinical Diagnostic Services (India) Clinical molecular diagnostic and genomic testing services provided in India through GenePath's NABL-approved laboratory in Pune. Spans infectious diseases, oncology, haematology, nephrology, neurology, reproductive health, and genetic disorders, with turnaround times from 1 day to 5 weeks depending on test complexity.
• Direct-to-Consumer HPV DNA Test (Beta) Consumer-focused, gynaecologist-approved self-collection DNA-based HPV test for home use in India. Targets educated women seeking private cervical cancer screening and addresses cultural barriers to clinical examination. Currently in beta release.

Quantifiable outcome

• Nearly 200,000 clinical and research samples tested since 2008
• +5 more outcomes

Named customers3 records

Segments5 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Four partnerships are on record, tiered core and minor.

• I-SHARE FoundationcoreStrategic or Co-development PartnerI-SHARE Foundation is a not-for-profit organization founded by Dr. Nikhil Phadke with mission to innovate solutions for healthcare access, research and education. They collaborate with GenePath on cervical cancer screening programs in Pune area, having screened over 4,300 women in 8 months. I-SHARE delivers last-mile healthcare to women in lower-income areas while GenePath provides diagnostic testing.
• PrayascoreStrategic or Co-development PartnerPrayas is an NGO working with GenePath and I-SHARE Foundation on cervical cancer screening initiatives targeting women in underserved Pune communities. Part of the ecosystem working to eliminate needless cervical cancer deaths.
• Gharda ChemicalsminorGTM or Marketing PartnerGharda Chemicals provides CSR funds for women's health screening programs as part of the cervical cancer elimination initiative in Pune. Their CSR funding enables free/subsidized screening for women in lower-income areas.
• HandyLab Alumni NetworkminorOthersHandyLab was a microfluidics-based molecular diagnostics startup in Ann Arbor, Michigan, acquired by Becton Dickinson. GenePath founder Dr. Nikhil Phadke was a core team member. HandyLab alumni network represents informal connections to industry expertise and diagnostics knowledge transfer.

Scale indicators8 records

Recent moves6 records

Expansion highlights7 records

Direct peers

• Strand Life Sciences: India-based genomics and clinical diagnostics provider spanning oncology, hereditary disease, and prenatal testing. Comparable peer as a domestic Indian competitor with overlapping oncology and genetic-disorder menus.
• Mylab Discovery Solutions: Indian molecular diagnostics company manufacturing PCR kits (including COVID and infectious disease multiplex assays) and offering diagnostic services. Direct peer in India's molecular diagnostics reagent and services market.
• MedGenome: India- and US-based genomics and molecular diagnostics company offering clinical services and genetic testing in oncology, reproductive health, and rare diseases. Closely comparable to GenePath's Indian clinical services business and global expansion profile.
• NeoGenomics: US-listed molecular diagnostics company providing oncology-focused genetic and molecular testing services, including hematology-oncology panels akin to GenePath's BCR-ABL and JAK2 assays.

Broad incumbents

• Hologic: Developer of FDA-cleared molecular diagnostic assays (including the Aptima HPV line) with broad women's health and infectious disease menus. Closely comparable to GenePath's HPV testing and infectious disease reagents.
• Bio-Rad Laboratories: Major manufacturer of qPCR reagents, digital PCR systems, and clinical diagnostics platforms. GenePath explicitly cites Bio-Rad instrument compatibility, making it a direct incumbent in the same reagent and consumables category.
• Qiagen: Global leader in molecular diagnostics reagents, sample technologies, and PCR/NGS workflows serving reference labs and clinical diagnostics customers. Directly comparable to GenePath's custom reagent business and broader infectious disease / oncology test menus.
• Roche Diagnostics: Global diagnostics incumbent with extensive molecular reagent, PCR/NGS platform, and HPV cervical screening offerings (cobas). Comparable to GenePath across both reagent portfolio and HPV screening ambitions.
• Cepheid (Danaher): Operates the GeneXpert molecular POCT platform widely deployed in infectious disease and AMR testing. A direct global incumbent to GenePath's respiratory, AMR, and CNS meningitis multiplex reagent lines.

Regional players

• Thyrocare Technologies: Indian high-volume diagnostic laboratory network with growing molecular testing capabilities. Regional peer serving overlapping Indian clinical diagnostics customer segments.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/genepathdx

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GenePath Dx